Press Release - Oslo, Norway, April 29, 2025: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces four abstract presentations at the AUA 2025,
highlighting the benefits of Blue Light Cystoscopy (BLC[®]), notably its impact
on management of the disease, improved risk stratification and therefore the
ability of the BLC procedure to help urologists and patients make well-informed
decisions. The American Urological Association Annual Congress 2025 was held
April 26-28, at the Venetian Convention & Expo Center in Las Vegas, NV, USA.

Three abstracts were presented from Photocure's U.S. Blue Light Cystoscopy with
Cysview Registry, a large multicenter bladder cancer patient registry of real
-world data, established by Photocure in 2014 and projected to enroll 4,400
patients. In addition, the study protocol of a randomized controlled non
-inferiority trial comparing a multidisciplinary approach including PDD-guided
primary TURBT to reduce the patients' burden of second resection including a
total of 327 patients has been presented. This investigator-initiated trial is
supported by Photocure.

The abstract sessions on Saturday, April 26:

"Upstaging and Risk Migration with BLC for NMIBC: Results from a prospective
multicenter registry" by Alireza Ghoreifi, Duke University

The study looked at 2,854 NMIBC* patients from the US Blue Light Cystoscopy with
Cysview Registry. A total of 201 (7%) patients had at least one malignant lesion
detected exclusively by BLC while having a negative WLC. These lesions (335 in
total) included carcinoma in-situ (CIS) (145